Drug intelligence / Profile preview

TF65

Development stage: Unknown
Lead developer: 深圳扬厉医药
Modality: Small Molecules

Overview

TF65 is a small molecule selective activated alkylating agent being developed by Zhejiang Yangli Pharmaceutical Technology (also known as VyBio). It is designed to target AIKLC3, a mechanism that likely involves the selective activation of an alkylating moiety within tumor cells, leading to DNA alkylation and crosslinking. This process exerts cytotoxic effects, ultimately resulting in tumor cell death. TF65 is currently in Phase 1 clinical development for the treatment of biliary tract cancer and adrenocortical carcinoma (ACC).

Targets

DNA

Beyond the preview

Go deeper on TF65.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TF65.

Explore the full profile